HELLO.

I'M Mark W Schwartz

An accomplished biotechnology executive, Mark W. Schwartz, PhD, has substantial experience in business development and operations. When he served as the president and CEO of Bayhill Therapeutics, Inc., from 2004 to 2009, the company developed a number of unique, new gene therapies. One of these, the DNA vaccine platform BHT-DNA, was designed for the treatment of several autoimmune diseases, and Mark W. Schwartz obtained regulatory approval for clinical trials in 16 countries and raised more than $100 million in venture capital and nondilutive capital to bring it to market. Dr. Schwartz previously held key management positions with Galena Biopharma, Inc., and Apthera, Inc.

Mark W. Schwartz holds a PhD in biochemistry from Arizona State University and a bachelor of arts in chemistry from Grinnell College. In his free time, he pursues hobbies that include reading, playing ice hockey, and wakeboarding. He draws on his business experience to serve as a board member for the biotechnology program at San Jose State University and as a guest lecturer with the Donald L. Wilson Program in Entrepreneurship and Leadership at Grinnell College.